Year Founded
2022
Ownership
Private
Employees
~50
Therapeutic Areas
OncologyImmunologyRare DiseasesCardiovascular
Stage
Preclinical
Modalities
Protein therapeutics

Diagonal Therapeutics General Information

Platform demonstrated utility across four receptor families. Lead program DIAG723 for HHT in development. Natural history study initiated for HHT.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office

Drug Pipeline

DIAG723
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Diagonal Therapeutics's pipeline data

Book a demo

Key Partnerships

Cure HHT

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Diagonal Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCApr 3, 2024$128.0MCompletedPreclinical
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Diagonal Therapeutics's complete valuation and funding history, request access »

Diagonal Therapeutics Investors

BVF Partners
Investor Type: Venture Capital
Holding: Minority
Atlas Venture
Investor Type: Venture Capital
Holding: Minority
Lightspeed Venture Partners
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 8 investors. Get the full list »